Key result
Andexanet alfa approval shifts bleeding management, highlighting ongoing evidence gaps in direct factor Xa trauma care.
Answers are grounded in this paper and cite their sources.
Andexanet alfa, a reversing agent for anticoagulants that inhibit factor Xa, has recently been licensed in the United States. We discuss the impact of this licensure on current practice and review in detail the problems of a neglected and growing clinical area: reversing the anticoagulation effect of factor Xa inhibitors in bleeding trauma patients. We identify areas of practice that need research so that care of bleeding trauma patients receiving direct factor Xa inhibitors can be improved.
No takes yet. Share an insight, caveat, or question.
Hunt et al. (2018) conducted a review in Bleeding trauma patients receiving direct factor Xa inhibitors. Andexanet alfa was evaluated. Andexanet alfa licensure impacts current practice, highlighting a critical need for further research to improve the care of bleeding trauma patients receiving direct factor Xa inhibitors.
Synapse has enriched 10 related papers. Consider them for comparative context: